©Reuters.
SARASOTA, Fla. – Oragenics (NYSE:), Inc. (NYSE American: OGEN), a pharmaceutical company specializing in intranasal treatments for neurological conditions, today announced that CEO Kimberly Murphy will be conducting a 2024 2 announced that he has resigned from his position as executive officer as of April 12th. Despite his resignation, Mr. Murphy will continue to contribute to the company as a member of the Board of Directors.
The move comes with assurances that Mr. Murphy's departure is not due to internal disputes regarding the company's operations, policies or practices. As part of the severance agreement, Ms. Murphy will receive benefits set out in her employment contract for her resignation without cause.
During this management change period, Charlie Pope, Chairman of the Board, will serve as Executive Chairman on an interim basis. Additionally, the company's president, Michael Redmond, was appointed interim chief operating officer on the same day.
Mr. Pope expressed his appreciation for Mr. Murphy's strategic leadership, particularly regarding the company's transition into neurology assets. He anticipates that her continued support will continue to have a positive impact on the company.
Oragenics is known for its focus on tackling infectious diseases such as COVID-19 and its variants, as well as developing nasal sprays for neurological diseases. The company's product candidates include ONP-002, which is aimed at treating mild traumatic brain injury (mTBI), and ONP-002, which is based on coronavirus spike protein research cleared by the National Security Agency, to treat mild traumatic brain injury (mTBI); NT-CoV2-1, an intranasal vaccine candidate designed to prevent (COVID-19). National Institutes of Health Research (NIH) and National Research Council of Canada (NRC).
This article was generated with the help of AI and reviewed by an editor. Please see our Terms of Use for more information.
